NCT01750216View on ClinicalTrials.gov

An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1

CompletedOBSERVATIONAL

Enrollment

196

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Hepatitis C, Chronic

Trial Locations (14)

85-030

Bydgoszcz

41-902

Bytom

41-500

Chorzów

06-400

Ciechanów

39-200

Dębica

40-752

Katowice

75-581

Koszalin

91-357

Lodz

39-300

Mielec

24-100

Puławy

26-600

Radom

04-141

Warsaw

58-300

Wałbrzych

37-100

Łańcut

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01750216 - An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 | Biotech Hunter | Biotech Hunter